Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEER trial of topical HT-001 for EGFR inhibitor-associated skin toxicities
2025-523058-16-00Phase 2Completed
- Sponsor
- Hoth Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of HT-001 in dermatologic toxicity (3 arms), sponsored by Hoth Therapeutics. Started Jan 2026; status: completed.
02
Drugs
HT-001
03
Conditions
dermatologic toxicity
Beyond the preview
Go deeper on 2025-523058-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523058-16-00.